Search

Your search keyword '"Geisbert, Thomas W."' showing total 7 results
Start Over Author "Geisbert, Thomas W." Publication Year Range This year
7 results on '"Geisbert, Thomas W."'

3. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates

Author

Zeitlin, Larry, primary, Cross, Robert W., additional, Woolsey, Courtney, additional, West, Brandyn R., additional, Borisevich, Viktoriya, additional, Agans, Krystle N., additional, Prasad, Abhishek N., additional, Deer, Daniel J., additional, Stuart, Lauren, additional, McCavitt-Malvido, Maria, additional, Kim, Do H., additional, Pettitt, James, additional, Crowe, James E., additional, Whaley, Kevin J., additional, Veesler, David, additional, Dimitrov, Antony, additional, Abelson, Dafna M., additional, Geisbert, Thomas W., additional, and Broder, Christopher C., additional

Published
2024
Full Text
View/download PDF

5. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus

Author

Cross, Robert W., primary, Woolsey, Courtney, additional, Chu, Victor C., additional, Babusis, Darius, additional, Bannister, Roy, additional, Vermillion, Meghan S., additional, Geleziunas, Romas, additional, Barrett, Kimberly T., additional, Bunyan, Elaine, additional, Nguyen, Anh-Quan, additional, Cihlar, Tomas, additional, Porter, Danielle P., additional, Prasad, Abhishek N., additional, Deer, Daniel J., additional, Borisevich, Viktoriya, additional, Agans, Krystle N., additional, Martinez, Jasmine, additional, Harrison, Mack B., additional, Dobias, Natalie S., additional, Fenton, Karla A., additional, Bilello, John P., additional, and Geisbert, Thomas W., additional

Published
2024
Full Text
View/download PDF

6. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates

Author

Woolsey, Courtney, primary, Cross, Robert W., additional, Prasad, Abhishek N., additional, Agans, Krystle N., additional, Borisevich, Viktoriya, additional, Deer, Daniel J., additional, Dobias, Natalie S., additional, Fears, Alyssa C., additional, Harrison, Mack B., additional, Heinrich, Megan L., additional, Fenton, Karla A., additional, Garry, Robert F., additional, Branco, Luis M., additional, and Geisbert, Thomas W., additional

Published
2024
Full Text
View/download PDF

7. A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure.

Author

Honko AN, Hunegnaw R, Moliva JI, Ploquin A, Dulan CNM, Murray T, Carr D, Foulds KE, Geisbert JB, Geisbert TW, Johnson JC, Wollen-Roberts SE, Trefry JC, Stanley DA, and Sullivan NJ

Abstract

Infection with Sudan virus (SUDV) is characterized by an aggressive disease course with case fatality rates between 40-100% and no approved vaccines or therapeutics. SUDV causes sporadic outbreaks in sub-Saharan Africa, including a recent outbreak in Uganda which has resulted in over 100 confirmed cases in one month. Prior vaccine and therapeutic efforts have historically prioritized Ebola virus (EBOV), leading to a significant gap in available treatments. Two vaccines, Erbevo ® and Zabdeno ® /Mvabea ® , are licensed for use against EBOV but are ineffective against SUDV. Recombinant adenovirus vector vaccines have been shown to be safe and effective against filoviruses, but efficacy depends on having low seroprevalence to the vector in the target human population. For this reason, and because of an excellent safety and immunogenicity profile, ChAd3 was selected as a superior vaccine vector. Here, a ChAd3 vaccine expressing the SUDV glycoprotein (GP) was evaluated for immunogenicity and efficacy in nonhuman primates. We demonstrate that a single dose of ChAd3-SUDV confers acute and durable protection against lethal SUDV challenge with a strong correlation between the SUDV GP-specific antibody titers and survival outcome. Additionally, we show that a bivalent ChAd3 vaccine encoding the GP from both EBOV and SUDV protects against both parenteral and aerosol lethal SUDV challenge. Our data indicate that the ChAd3-SUDV vaccine is a suitable candidate for a prophylactic vaccination strategy in regions at high risk of filovirus outbreaks. One Sentence Summary: A single-dose of ChAd3 vaccine protected macaques from lethal challenge with Sudan virus (SUDV) by parenteral and aerosol routes of exposure.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results